NCT01408342

Alemtuzumab and Rituximab in Aplastic Anemia

Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
• Sex: All
• Age: 12 Months
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

Conditions

• Aplastic Anemia

Interventions

Type	Name	Description
DRUG	Alemtuzumab and Rituximab	* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3 * Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25 * Cyclosporine 3 mg/kg starting day 21

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-01-01
• Completion: 2014-01-01
• First posted: 2011-08-03
• Last updated: 2014-01-07

Locations

1 site across 1 country: Mexico